Can zebrafish be used as animal model to study Alzheimer's disease?

American Journal of Neurodegenerative Diseases

Volumn 1, Issue 1, 2012, Pages 32-48

  Santana, Soraya ^a   Rico, Eduardo P ^b   Burgos, Javier S ^a  

^a BioPharma Division   (Spain)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Alzheimer's disease; Apolipoprotein E; APP; Cholinergic neurotransmission; GABAergic neurotransmission; Glutamatergic neurotransmission; Neurotoxins; Presenilin; TAU; Zebrafish

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; APOLIPOPROTEIN E; KETAMINE; NEUROTOXIN; NICASTRIN; PENTETRAZOLE; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN; CENTRAL NERVOUS SYSTEM; CHOLINERGIC TRANSMISSION; DEGENERATIVE DISEASE; EXPERIMENTAL MODEL; GENE; GENE EXPRESSION; MICROTUBULE; MUTANT; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; REVIEW; RISK FACTOR; SEQUENCE HOMOLOGY; TRANSGENIC ANIMAL; ZEBRA FISH;

EID: 84980053710     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Blennow K, de Leon MJ and Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
2. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL and Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923.
4. Bowman TV and Zon LI. Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem Biol 2010; 5: 159-161.
5. Rico EP, Rosemberg DB, Seibt KJ, Capiotti KM, Da Silva RS and Bonan CD. Zebrafish neurotransmitter systems as potential pharmacological and toxicological targets. Neurotoxicol Teratol 2011; 33: 608-617.
6. Newman M, Verdile G, Martins RN and Lardelli M. Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta 2011; 1812: 346-352.
7. Barbazuk WB, Korf I, Kadavi C, Heyen J, Tate S, Wun E, Bedell JA, McPherson JD and Johnson SL. The syntenic relationship of the zebrafish and human genomes. Genome Res 2000; 10: 1351-1358.
8. Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish? Genes Brain Behav 2004; 3: 63-74.
9. Nasevicius A and Ekker SC. Effective targeted gene 'knockdown' in zebrafish. Nat Genet 2000; 26: 216-220.
10. Eisen JS and Smith JC. Controlling morpholino experiments: don't stop making antisense. Development 2008; 135: 1735-1743.
11. Zon LI and Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4: 35-44.
12. Panula P, Sallinen V, Sundvik M, Kolehmainen J, Torkko V, Tiittula A, Moshnyakov M and Podlasz P. Modulatory neurotransmitter systems and behavior: towards zebrafish models of neurodegenerative diseases. Zebrafish 2006; 3: 235-247.
13. Lieschke GJ and Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 2007; 8: 353-367.
14. Grunwald DJ and Eisen JS. Headwaters of the zebrafish--emergence of a new model vertebrate. Nat Rev Genet 2002; 3: 717-724.
15. M. F Wullimann BR, H. Reichert. Neuroanatomy of the Zebrafish Brain. 1996; Birkhauser-Verlag, Berlín.
16. Mueller T and Wullimann MF. An evolutionary interpretation of teleostean forebrain anatomy. Brain Behav Evol 2009; 74: 30-42.
17. Rink E and Wullimann MF. Connections of the ventral telencephalon (subpallium) in the zebrafish (Danio rerio). Brain Res 2004; 1011: 206-220.
18. Mueller T, Vernier P and Wullimann MF. The adult central nervous cholinergic system of a neurogenetic model animal, the zebrafish Danio rerio. Brain Res 2004; 1011: 156-169.
19. Park E, Lee Y, Kim Y and Lee CJ. Cholinergic modulation of neural activity in the telencephalon of the zebrafish. Neurosci Lett 2008; 439: 79-83.
20. Peri F and Nusslein-Volhard C. Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. Cell 2008; 133: 916-927.
21. Avila RL, Tevlin BR, Lees JP, Inouye H and Kirschner DA. Myelin structure and composition in zebrafish. Neurochem Res 2007; 32: 197-209.
22. Yoshida M and Macklin WB. Oligodendrocyte development and myelination in GFPtransgenic zebrafish. J Neurosci Res 2005; 81: 1-8.
23. Koulen P, Janowitz T, Johnston LD and Ehrlich BE. Conservation of localization patterns of IP (3) receptor type 1 in cerebellar Purkinje cells across vertebrate species. J Neurosci Res 2000; 61: 493-499.
24. Westerfield M, McMurray JV and Eisen JS. Identified motoneurons and their innervation of axial muscles in the zebrafish. J Neurosci 1986; 6: 2267-2277.
25. Kawai H, Arata N and Nakayasu H. Threedimensional distribution of astrocytes in zebrafish spinal cord. Glia 2001; 36: 406-413.
26. Jeong JY, Kwon HB, Ahn JC, Kang D, Kwon SH, Park JA and Kim KW. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res Bull 2008; 75: 619-628.
27. Eliceiri BP, Gonzalez AM and Baird A. Zebrafish model of the blood-brain barrier: morphological and permeability studies. Methods Mol Biol 2011; 686: 371-378.
28. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P and Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-760.
29. Auld DS, Kornecook TJ, Bastianetto S and Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to betaamyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209-245.
30. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30: 895-908.
31. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P and Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 893-903.
32. Clemente D, Porteros A, Weruaga E, Alonso JR, Arenzana FJ, Aijon J and Arevalo R. Cholinergic elements in the zebrafish central nervous system: Histochemical and immunohistochemical analysis. J Comp Neurol 2004; 474: 75-107.
33. Portavella M, Vargas JP, Torres B and Salas C. The effects of telencephalic pallial lesions on spatial, temporal, and emotional learning in goldfish. Brain Res Bull 2002; 57: 397-399.
34. Rodriguez F, Lopez JC, Vargas JP, Broglio C, Gomez Y and Salas C. Spatial memory and hippocampal pallium through vertebrate evolution: insights from reptiles and teleost fish. Brain Res Bull 2002; 57: 499-503.
35. Kaslin J, Nystedt JM, Ostergard M, Peitsaro N and Panula P. The orexin/hypocretin system in zebrafish is connected to the aminergic and cholinergic systems. J Neurosci 2004; 24: 2678-2689.
36. Arenzana FJ, Clemente D, Sanchez-Gonzalez R, Porteros A, Aijon J and Arevalo R. Development of the cholinergic system in the brain and retina of the zebrafish. Brain Res Bull 2005; 66: 421-425.
37. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105.
38. Maragakis NJ and Rothstein JD. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 2004; 15: 461-473.
39. Hu NW, Ondrejcak T and Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav 2012; 100: 855-862.
40. Cox JA, Kucenas S and Voigt MM. Molecular characterization and embryonic expression of the family of N-methyl-D-aspartate receptor subunit genes in the zebrafish. Dev Dyn 2005; 234: 756-766.
41. Nam RH, Kim W and Lee CJ. NMDA receptordependent long-term potentiation in the telencephalon of the zebrafish. Neurosci Lett 2004; 370: 248-251.
42. Blank M, Guerim LD, Cordeiro RF and Vianna MR. A one-trial inhibitory avoidance task to zebrafish: rapid acquisition of an NMDAdependent long-term memory. Neurobiol Learn Mem 2009; 92: 529-534.
43. Seibt KJ, da Luz Oliveira R, Rosemberg DB, Savio LE, Scherer EB, Schmitz F, Wyse AT and Bonan CD. MK-801 alters Na(+), K (+)-ATPase activity and oxidative status in zebrafish brain: reversal by antipsychotic drugs. J Neural Transm 2011
44. Edwards JG and Michel WC. Pharmacological characterization of ionotropic glutamate receptors in the zebrafish olfactory bulb. Neuroscience 2003; 122: 1037-1047.
45. Tabor R and Friedrich RW. Pharmacological analysis of ionotropic glutamate receptor function in neuronal circuits of the zebrafish olfactory bulb. PLoS One 2008; 3: e1416.
46. Rico EP, de Oliveira DL, Rosemberg DB, Mussulini BH, Bonan CD, Dias RD, Wofchuk S, Souza DO and Bogo MR. Expression and functional analysis of Na(+)-dependent glutamate transporters from zebrafish brain. Brain Res Bull 2010; 81: 517-523.
47. Staley KJ, Soldo BL and Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 1995; 269: 977-981.
48. Luddens H, Korpi ER and Seeburg PH. GABAA/ benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 1995; 34: 245-254.
49. Mori H and Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34: 1219-1237.
50. Rissman RA, De Blas AL and Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J Neurochem 2007; 103: 1285-1292.
51. Lanctot KL, Herrmann N, Mazzotta P, Khan LR and Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49: 439-453.
52. Kim YJ, Nam RH, Yoo YM and Lee CJ. Identification and functional evidence of GABAergic neurons in parts of the brain of adult zebrafish (Danio rerio). Neurosci Lett 2004; 355: 29-32.
53. Delgado L and Schmachtenberg O. Immunohistochemical localization of GABA, GAD65, and the receptor subunits GABAAalpha1 and GABAB1 in the zebrafish cerebellum. Cerebellum 2008; 7: 444-450.
54. Connaughton VP, Nelson R and Bender AM. Electrophysiological evidence of GABAA and GABAC receptors on zebrafish retinal bipolar cells. Vis Neurosci 2008; 25: 139-153.
55. Doldan MJ, Prego B, Holmqvist BI and de Miguel E. Distribution of GABA-immunolabeling in the early zebrafish (Danio rerio) brain. Eur J Morphol 1999; 37: 126-129.
56. Jackson FR, Newby LM and Kulkarni SJ. Drosophila GABAergic systems: sequence and expression of glutamic acid decarboxylase. J Neurochem 1990; 54: 1068-1078.
57. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N and Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron 1991; 7: 91-100.
58. Martin SC, Heinrich G and Sandell JH. Sequence and expression of glutamic acid decarboxylase isoforms in the developing zebrafish. J Comp Neurol 1998; 396: 253-266.
59. Hanneman E and Westerfield M. Early expression of acetylcholinesterase activity in functionally distinct neurons of the zebrafish. J Comp Neurol 1989; 284: 350-361.
60. Rico EP, Rosemberg DB, Senger MR, Arizi Mde B, Bernardi GF, Dias RD, Bogo MR and Bonan CD. Methanol alters ecto-nucleotidases and acetylcholinesterase in zebrafish brain. Neurotoxicol Teratol 2006; 28: 489-496.
61. Senger MR, Rico EP, de Bem Arizi M, Frazzon AP, Dias RD, Bogo MR and Bonan CD. Exposure to Hg2+ and Pb2+ changes NTPDase and ecto-5'-nucleotidase activities in central nervous system of zebrafish (Danio rerio). Toxicology 2006; 226: 229-237.
62. Senger MR, Rosemberg DB, Rico EP, de Bem Arizi M, Dias RD, Bogo MR and Bonan CD. In vitro effect of zinc and cadmium on acetylcholinesterase and ectonucleotidase activities in zebrafish (Danio rerio) brain. Toxicol In Vitro 2006; 20: 954-958.
63. Richetti SK, Blank M, Capiotti KM, Piato AL, Bogo MR, Vianna MR and Bonan CD. Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish. Behav Brain Res 2011; 217: 10-15.
64. Siebel AM, Rico EP, Capiotti KM, Piato AL, Cusinato CT, Franco TM, Bogo MR and Bonan CD. In vitro effects of antiepileptic drugs on acetylcholinesterase and ectonucleotidase activities in zebrafish (Danio rerio) brain. Toxicol In Vitro 2010; 24: 1279-1284.
65. Rico EP, Rosemberg DB, Dias RD, Bogo MR and Bonan CD. Ethanol alters acetylcholinesterase activity and gene expression in zebrafish brain. Toxicol Lett 2007; 174: 25-30.
66. Kim YH, Lee Y, Kim D, Jung MW and Lee CJ. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. Neurosci Res 2010; 67: 156-161.
67. Janas AM, Cunningham SC, Duffy KB, Devan BD, Greig NH, Holloway HW, Yu QS, Markowska AL, Ingram DK and Spangler EL. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolaminetreated rats. Life Sci 2005; 76: 1073-1081.
68. Xu J, Rong S, Xie B, Sun Z, Zhang L, Wu H, Yao P, Zhang Y and Liu L. Procyanidins extracted from the lotus seedpod ameliorate scopolamine-induced memory impairment in mice. Phytother Res 2009; 23: 1742-1747.
69. Eidi M, Zarrindast MR, Eidi A, Oryan S and Pari var K. Effects of histamine and cholinergic systems on memory retention of passive avoidance learning in rats. Eur J Pharmacol 2003; 465: 91-96.
70. Williams FE and Messer WS, Jr. Muscarinic acetylcholine receptors in the brain of the zebrafish (Danio rerio) measured by radioligand binding techniques. Comp Biochem Physiol C Toxicol Pharmacol 2004; 137: 349-353.
71. Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, Michotte Y, Crawford AD, Esguerra CV, de Witte PA, Smolders I and Clinckers R. Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models. Epilepsy Behav 2011; 22: 450-460.
72. Eddins D, Cerutti D, Williams P, Linney E and Levin ED. Zebrafish provide a sensitive model of persisting neurobehavioral effects of developmental chlorpyrifos exposure: comparison with nicotine and pilocarpine effects and relationship to dopamine deficits. Neurotoxicol Teratol 2010; 32: 99-108.
73. Kim YH, Lee Y, Lee K, Lee T, Kim YJ and Lee CJ. Reduced neuronal proliferation by proconvulsant drugs in the developing zebrafish brain. Neurotoxicol Teratol 2010; 32: 551-557.
74. Parsons CG, Stoffler A and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723.
75. Greenamyre JT and Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989; 10: 593-602.
76. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE and Bateman RJ. Decreased clearance of CNS betaamyloid in Alzheimer's disease. Science 2010; 330: 1774.
77. Swain HA, Sigstad C and Scalzo FM. Effects of dizocilpine (MK-801) on circling behavior, swimming activity, and place preference in zebrafish (Danio rerio). Neurotoxicol Teratol 2004; 26: 725-729.
78. Edwards JG and Michel WC. Odor-stimulated glutamatergic neurotransmission in the zebrafish olfactory bulb. J Comp Neurol 2002; 454: 294-309.
79. Ng MC, Tang TH, Ko MC, Wu YJ, Hsu CP, Yang YL and Lu KT. Stimulation of the lateral division of the dorsal telencephalon induces synaptic plasticity in the medial division of adult zebrafish. Neurosci Lett 2012; 512: 109-113.
80. Alfaro JM, Ripoll-Gomez J and Burgos JS. Kainate administered to adult zebrafish causes seizures similar to those in rodent models. Eur J Neurosci 2011; 33: 1252-1255.
81. Tiedeken JA, Ramsdell JS and Ramsdell AF. Developmental toxicity of domoic acid in zebrafish (Danio rerio). Neurotoxicol Teratol 2005; 27: 711-717.
82. Peng YG, Taylor TB, Finch RE, Switzer RC and Ramsdell JS. Neuroexcitatory and neurotoxic actions of the amnesic shellfish poison, domoic acid. Neuroreport 1994; 5: 981-985.
83. Tiedeken JA and Ramsdell JS. Embryonic exposure to domoic Acid increases the susceptibility of zebrafish larvae to the chemical convulsant pentylenetetrazole. Environ Health Perspect 2007; 115: 1547-1552.
84. Best JD, Berghmans S, Hunt JJ, Clarke SC, Fleming A, Goldsmith P and Roach AG. Nonassociative learning in larval zebrafish. Neuropsychopharmacology 2008; 33: 1206-1215.
85. Chen J, Patel R, Friedman TC and Jones KS. The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae. Int J Comp Psychol 2010; 23: 82-90.
86. Brown TC, Cole WH and Murray GH. Ketamine: A new anaesthetic agent. Aust N Z J Surg 1970; 39: 305-310.
87. Finck AD and Ngai SH. Opiate receptor mediation of ketamine analgesia. Anesthesiology 1982; 56: 291-297.
88. Zakhary SM, Ayubcha D, Ansari F, Kamran K, Karim M, Leheste JR, Horowitz JM and Torres G. A behavioral and molecular analysis of ketamine in zebrafish. Synapse 2011; 65: 160-167.
89. Riehl R, Kyzar E, Allain A, Green J, Hook M, Monnig L, Rhymes K, Roth A, Pham M, Razavi R, Dileo J, Gaikwad S, Hart P and Kalueff AV. Behavioral and physiological effects of acute ketamine exposure in adult zebrafish. Neurotoxicol Teratol 2011; 33: 658-667.
90. Kanungo J, Cuevas E, Ali SF and Paule MG. Ketamine induces motor neuron toxicity and alters neurogenic and proneural gene expression in zebrafish. J Appl Toxicol 2011
91. Stehr CM, Linbo TL, Incardona JP and Scholz NL. The developmental neurotoxicity of fipronil: notochord degeneration and locomotor defects in zebrafish embryos and larvae. Toxicol Sci 2006; 92: 270-278.
92. Leweke FM, Louvel J, Rausche G and Heinemann U. Effects of pentetrazol on neuronal activity and on extracellular calcium concentration in rat hippocampal slices. Epilepsy Res 1990; 6: 187-198.
93. Baraban SC, Taylor MR, Castro PA and Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005; 131: 759-768.
94. Pearl PL, Shukla L, Theodore WH, Jakobs C and Michael Gibson K. Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev 2011; 33: 796-805.
95. Wong K, Stewart A, Gilder T, Wu N, Frank K, Gaikwad S, Suciu C, Dileo J, Utterback E, Chang K, Grossman L, Cachat J and Kalueff AV. Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish. Brain Res 2010; 1348: 209-215.
96. Lee Y, Kim D, Kim YH, Lee H and Lee CJ. Improvement of pentylenetetrazol-induced learning deficits by valproic acid in the adult zebrafish. Eur J Pharmacol 2010; 643: 225-231.
97. Ellis LD, Seibert J and Soanes KH. Distinct models of induced hyperactivity in zebrafish larvae. Brain Res 2012
98. Donnini S, Solito R, Cetti E, Corti F, Giachetti A, Carra S, Beltrame M, Cotelli F and Ziche M. Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. Faseb J 2010; 24: 2385-2395.
99. Chambon C, Wegener N, Gravius A and Danysz W. Behavioural and cellular effects of exogenous amyloid-beta peptides in rodents. Behav Brain Res 2011; 225: 623-641.
100. Braidy N, Munoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P and Guillemin GJ. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm 2012; 119: 173-195.
101. Obulesu M, Venu R and Somashekhar R. Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology. Neurochem Res 2011; 36: 1329-1335.
102. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA and Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011; 23: 307-318.
103. Zhang Z and Simpkins JW. An okadaic acidinduced model of tauopathy and cognitive deficiency. Brain Res 2010; 1359: 233-246.
104. Costa AP, Tramontina AC, Biasibetti R, Batassini C, Lopes MW, Wartchow KM, Bernardi C, Tortorelli LS, Leal RB and Goncalves CA. Neuroglial alterations in rats submitted to the okadaic acid-induced model of dementia. Behav Brain Res 2012; 226: 420-427.
105. Postlethwait JH, Woods IG, Ngo-Hazelett P, Yan YL, Kelly PD, Chu F, Huang H, Hill-Force A and Talbot WS. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome Res 2000; 10: 1890-1902.
106. Sprague J, Bayraktaroglu L, Bradford Y, Conlin T, Dunn N, Fashena D, Frazer K, Haendel M, Howe DG, Knight J, Mani P, Moxon SA, Pich C, Ramachandran S, Schaper K, Segerdell E, Shao X, Singer A, Song P, Sprunger B, Van Slyke CE and Westerfield M. The Zebrafish Information Network: the zebrafish model organism database provides expanded support for genotypes and phenotypes. Nucleic Acids Res 2008; 36: D768-772.
107. Kyzar E, Zapolsky I, Green J, Gaikwad S, Pham M, Collins C, Roth A, Stewart AM, St-Pierre P, Hirons B and Kalueff AV. The Zebrafish Neurophenome Database (ZND): A Dynamic Open-Access Resource for Zebrafish Neurophenotypic Data. Zebrafish 2011; 9: 8-14.
108. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
109. Haass C. Take five--BACE and the gammasecretase quartet conduct Alzheimer's amyloid beta-peptide generation. Embo J 2004; 23: 483-488.
110. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N and Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45-53.
111. Musa A, Lehrach H and Russo VA. Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev Genes Evol 2001; 211: 563-567.
112. Guo Q, Wang Z, Li H, Wiese M and Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res 2011; 22: 78-89.
113. Lee JA and Cole GJ. Generation of transgenic zebrafish expressing green fluorescent protein under control of zebrafish amyloid precursor protein gene regulatory elements. Zebrafish 2007; 4: 277-286.
114. Joshi P, Liang JO, DiMonte K, Sullivan J and Pimplikar SW. Amyloid precursor protein is required for convergent-extension movements during Zebrafish development. Dev Biol 2009; 335: 1-11.
115. Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R and Haass C. Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nat Cell Biol 2000; 2: 205-211.
116. Selkoe DJ and Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002; 3: 67-99.
117. Walker ES, Martinez M, Brunkan AL and Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem 2005; 92: 294-301.
118. Leimer U, Lun K, Romig H, Walter J, Grunberg J, Brand M and Haass C. Zebrafish (Danio rerio) presenilin promotes aberrant amyloid betapeptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry 1999; 38: 13602-13609.
119. Groth C, Nornes S, McCarty R, Tamme R and Lardelli M. Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer's disease gene presenilin2. Dev Genes Evol 2002; 212: 486-490.
120. Nornes S, Groth C, Camp E, Ey P and Lardelli M. Developmental control of Presenilin1 expression, endoproteolysis, and interaction in zebraf ish embryos. Exp Cell Res 2003; 289: 124-132.
121. Campbell WA, Yang H, Zetterberg H, Baulac S, Sears JA, Liu T, Wong ST, Zhong TP and Xia W. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J Neurochem 2006; 96: 1423-1440.
122. van Tijn P, Kamphuis W, Marlatt MW, Hol EM and Lucassen PJ. Presenilin mouse and zebrafish models for dementia: focus on neurogenesis. Prog Neurobiol 2011; 93: 149-164.
123. Nornes S, Newman M, Verdile G, Wells S, Stoick-Cooper CL, Tucker B, Frederich-Sleptsova I, Martins R and Lardelli M. Interference with splicing of Presenilin transcripts has potent dominant negative effects on Presenilin activity. Hum Mol Genet 2008; 17: 402-412.
124. Nornes S, Newman M, Wells S, Verdile G, Martins RN and Lardelli M. Independent and cooperative action of Psen2 with Psen1 in zebrafish embryos. Exp Cell Res 2009; 315: 2791-2801.
125. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003; 38: 9-12.
126. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H and Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003; 5: 486-488.
127. De Strooper B and Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010; 26: 235-260.
128. Sager JJ, Bai Q and Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct 2010; 214: 285-302.
129. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS and Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002; 3: 85-97.
130. Avila J, Lucas JJ, Perez M and Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84: 361-384.
131. Brandt R, Hundelt M and Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta 2005; 1739: 331-354.
132. Wang JZ and Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008; 85: 148-175.
133. Chun W and Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 2007; 12: 733-756.
134. Bai Q and Burton EA. Zebrafish models of Tauopathy. Biochim Biophys Acta 2011; 1812: 353-363.
135. Chen M, Martins RN and Lardelli M. Complex splicing and neural expression of duplicated tau genes in zebrafish embryos. J Alzheimers Dis 2009; 18: 305-317.
136. Bai Q, Garver JA, Hukriede NA and Burton EA. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res 2007; 35: 6501-6516.
137. Tomasiewicz HG, Flaherty DB, Soria JP and Wood JG. Transgenic zebrafish model of neurodegeneration. J Neurosci Res 2002; 70: 734-745.
138. Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, Falting J, Distel M, Koster RW, Schmid B and Haass C. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 2009; 119: 1382-1395.
139. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ and et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
140. Verghese PB, Castellano JM and Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-252.
141. Kim J, Basak JM and Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
142. Durliat M, Andre M and Babin PJ. Conserved protein motifs and structural organization of a fish gene homologous to mammalian apolipoprotein E. Eur J Biochem 2000; 267: 549-559.
143. Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA and Thisse B. Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Proc Natl Acad Sci U S A 1997; 94: 8622-8627.
144. Monnot MJ, Babin PJ, Poleo G, Andre M, Laforest L, Ballagny C and Akimenko MA. Epidermal expression of apolipoprotein E gene during fin and scale development and fin regeneration in zebrafish. Dev Dyn 1999; 214: 207-215.